Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa RSV human challenge study of EDP-323
ISRCTN62572873Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of EDP-323 in respiratory syncytial virus disease (RSV), sponsored by Enanta Pharmaceuticals. Started Sep 2023; status: completed.
02
Drugs
EDP-323
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on ISRCTN62572873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62572873.